ArticleFrontiers in endocrinology2026
Glycemic variability associated with gamma secretase inhibitor therapy in a type 1 diabetic patient undergoing treatment for desmoid tumor: a case report.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Desmoid tumors, also known as aggressive fibromatosis, are rare, locally invasive soft tissue neoplasms characterized by clonal fibroblastic proliferation without metastatic potential. Gamma secretase inhibitors (GSIs) are currently being investigated for use in desmoid tumor therapy. This therapy targets the Notch pathway which is associated with this tumor's pathogenesis can affect tumor growth, glucose metabolism and insulin sensitivity. Current data on this association is limited and has only been described Case description: A 31-year-old female with previously well controlled Type 1 Diabetes Mellitus and left breast desmoid tumor presented with new onset glycemic variability after enrollment in a clinical trial involving a gamma secretase inhibitor. While on therapy, her clinical course was complicated by fluctuating glycemic control with recurrent diabetic ketoacidosis and hypoglycemic episodes requiring frequent adjustments to her insulin therapy. Her glycemic control stabilized after being disenrolled from the clinical trial. Conclusion: We present a real-world case describing the association of GSIs with glycemic instability. Prior studies (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.